董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Hariri | 男 | Chairman of the Board and Chief Executive Officer and Director | 67 | 65.07万美元 | 393.24 | 2026-10-20 |
| Peter Diamandis | 男 | Director | 65 | 41.08万美元 | 68.56 | 2026-10-20 |
| Diane Parks | 女 | Director | 73 | 43.53万美元 | 51.72 | 2026-10-20 |
| Steven N. Gordon | 男 | Chief Operating and Administrative Officer and Director | 59 | 未披露 | 未持股 | 2026-10-20 |
| Philip A. Barach | 男 | Director | 74 | 未披露 | 1194.02 | 2026-10-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Hariri | 男 | Chairman of the Board and Chief Executive Officer and Director | 67 | 65.07万美元 | 393.24 | 2026-10-20 |
| K. Harold Fletcher | 男 | Chief Legal and Strategy Officer and Corporate Secretary | 41 | 未披露 | 10.15 | 2026-10-20 |
| John M. Sprague | 男 | Chief Financial Officer | 67 | 未披露 | 未持股 | 2026-10-20 |
| Steven N. Gordon | 男 | Chief Operating and Administrative Officer and Director | 59 | 未披露 | 未持股 | 2026-10-20 |
董事简历
中英对照 | 中文 | 英文- Robert J. Hariri
-
Robert J. Hariri，是Legacy cellular的创始人，曾担任Celularity Inc.的董事。自2021年7月业务合并以来，他一直担任cellular Inc.的首席执行官兼董事长，自业务合并以来一直担任总裁，直到2021年9月，在业务合并之前，他是Legacy cellular的创始人，此前曾担任其总裁兼首席执行官，自2016年起担任董事会主席。Hariri博士从2015年9月起担任Cryoport的董事，从2020年6月起担任Biovie的董事。在加入Legacy Cellular之前，Hariri博士创立了Anthrogenesis Corporation并担任首席执行官，在该公司被Celgene收购后，Hariri博士从2005年到2013年担任Celgene Cellular Therapeutics的首席执行官。Hariri博士还共同创立了基于基因组的健康智能公司Human Longevity， Inc.和专注于长寿的Fountainlife。Hariri博士也是威尔-康奈尔大学医学院的神经外科兼职教授和研究员委员会成员。他是基因组学执政官X奖的X奖基金会科学顾问委员会成员。哈里里博士曾担任自由科学中心的受托人兼副主席。Hariri博士曾担任多家公司的董事会成员，包括Myos Corporation（2011年7月至2020年11月），2012年4月至2020年11月担任董事会主席，Bionik Laboratories Corp.（2015年3月至2017年10月）。Hariri博士获得哥伦比亚大学工程与应用科学学院和哥伦比亚学院生物人类学学士学位，以及Cornell大学医学博士和博士学位。
Robert J. Hariri is the founder of Celularity and has served as Celularity Inc.'s Chief Executive Officer and Chairman of the board of directors since the July 2021 business combination, after serving in those roles at Legacy Celularity from 2016. Dr. Hariri has also served as a director at BioVie since June 2020. Prior to joining Celularity, Dr. Hariri founded and served as Chief Executive Officer of Anthrogenesis Corporation, and after its acquisition by Celgene, Dr. Hariri served as Chief Executive Officer of Celgene Cellular Therapeutics from 2005 to 2013. Dr. Hariri also co founded the genomic based health intelligence company, Human Longevity, Inc. Dr. Hariri is also an Adjunct Professor of Neurosurgery and a member of the Board of Overseers at the Weill Cornell University Medical College. He is a member of the XPRIZE Foundation scientific advisory board for the Archon XPRIZE for Genomics. Dr. Hariri is a trustee and vice chair of the Liberty Science Center. Dr. Hariri has served as a member of the board of directors of various companies, including Myos Corporation from July 2011 to November 2020, where he served as Chairman of the board from April 2012 to November 2020, Bionik Laboratories Corp. from March 2015 to October 2017, Cryoport since September 2015. Dr. Hariri obtained an A.B. in Biological Anthropology from Columbia University School of Engineering and Applied Sciences and Columbia College and an M.D. and Ph.D. from Cornell University. - Robert J. Hariri，是Legacy cellular的创始人，曾担任Celularity Inc.的董事。自2021年7月业务合并以来，他一直担任cellular Inc.的首席执行官兼董事长，自业务合并以来一直担任总裁，直到2021年9月，在业务合并之前，他是Legacy cellular的创始人，此前曾担任其总裁兼首席执行官，自2016年起担任董事会主席。Hariri博士从2015年9月起担任Cryoport的董事，从2020年6月起担任Biovie的董事。在加入Legacy Cellular之前，Hariri博士创立了Anthrogenesis Corporation并担任首席执行官，在该公司被Celgene收购后，Hariri博士从2005年到2013年担任Celgene Cellular Therapeutics的首席执行官。Hariri博士还共同创立了基于基因组的健康智能公司Human Longevity， Inc.和专注于长寿的Fountainlife。Hariri博士也是威尔-康奈尔大学医学院的神经外科兼职教授和研究员委员会成员。他是基因组学执政官X奖的X奖基金会科学顾问委员会成员。哈里里博士曾担任自由科学中心的受托人兼副主席。Hariri博士曾担任多家公司的董事会成员，包括Myos Corporation（2011年7月至2020年11月），2012年4月至2020年11月担任董事会主席，Bionik Laboratories Corp.（2015年3月至2017年10月）。Hariri博士获得哥伦比亚大学工程与应用科学学院和哥伦比亚学院生物人类学学士学位，以及Cornell大学医学博士和博士学位。
- Robert J. Hariri is the founder of Celularity and has served as Celularity Inc.'s Chief Executive Officer and Chairman of the board of directors since the July 2021 business combination, after serving in those roles at Legacy Celularity from 2016. Dr. Hariri has also served as a director at BioVie since June 2020. Prior to joining Celularity, Dr. Hariri founded and served as Chief Executive Officer of Anthrogenesis Corporation, and after its acquisition by Celgene, Dr. Hariri served as Chief Executive Officer of Celgene Cellular Therapeutics from 2005 to 2013. Dr. Hariri also co founded the genomic based health intelligence company, Human Longevity, Inc. Dr. Hariri is also an Adjunct Professor of Neurosurgery and a member of the Board of Overseers at the Weill Cornell University Medical College. He is a member of the XPRIZE Foundation scientific advisory board for the Archon XPRIZE for Genomics. Dr. Hariri is a trustee and vice chair of the Liberty Science Center. Dr. Hariri has served as a member of the board of directors of various companies, including Myos Corporation from July 2011 to November 2020, where he served as Chairman of the board from April 2012 to November 2020, Bionik Laboratories Corp. from March 2015 to October 2017, Cryoport since September 2015. Dr. Hariri obtained an A.B. in Biological Anthropology from Columbia University School of Engineering and Applied Sciences and Columbia College and an M.D. and Ph.D. from Cornell University.
- Peter Diamandis
-
Peter Diamandis，自2021年7月业务合并以来，他一直担任Celularity Inc.董事会成员。Diamandis博士是Legacy cellular的联合创始人，自2016年起担任其董事会副主席。他也是XPRIZE Foundation的创始人和执行主席，这是一家设计和运营大规模激励竞赛的非营利基金会，也是奇点大学的执行创始人，奇点大学是一家成立于2008年的研究生水平的硅谷机构，为世界领导人提供指数增长技术方面的建议。Diamandis博士是Human Longevity， Inc.（一家专注于延长人类寿命的公司）的副董事长兼联合创始人。他目前担任Vaxxinity和DPCM Capital以及SWAG III（纳斯达克股票代码：SWAG）的董事会成员。他获得麻省理工学院分子工程和航空航天工程学位，以及哈佛医学院医学博士学位。
Peter Diamandis has served as a member of Celularity Inc.'s board of directors since the July 2021 business combination. Dr. Diamandis was a co founder of Legacy Celularity and served as Vice Chairman of its board of directors from 2016. Dr. Diamandis is also the Founder and Executive Chairman of the XPRIZE Foundation, a non profit foundation that has designed and operated large scale incentive competitions and the Executive Founder of Singularity University, a graduate level Silicon Valley institution founded in 2008 that counsels the world's leaders on exponentially growing technologies. Dr. Diamandis is the Vice Chairman and co Founder of Human Longevity, Inc., a company focused on extending the human lifespan. Dr. Diamandis currently serves on the boards of Vaxxinity and DPCM Capital, and SWAG III (Nasdaq: SWAG). - Peter Diamandis，自2021年7月业务合并以来，他一直担任Celularity Inc.董事会成员。Diamandis博士是Legacy cellular的联合创始人，自2016年起担任其董事会副主席。他也是XPRIZE Foundation的创始人和执行主席，这是一家设计和运营大规模激励竞赛的非营利基金会，也是奇点大学的执行创始人，奇点大学是一家成立于2008年的研究生水平的硅谷机构，为世界领导人提供指数增长技术方面的建议。Diamandis博士是Human Longevity， Inc.（一家专注于延长人类寿命的公司）的副董事长兼联合创始人。他目前担任Vaxxinity和DPCM Capital以及SWAG III（纳斯达克股票代码：SWAG）的董事会成员。他获得麻省理工学院分子工程和航空航天工程学位，以及哈佛医学院医学博士学位。
- Peter Diamandis has served as a member of Celularity Inc.'s board of directors since the July 2021 business combination. Dr. Diamandis was a co founder of Legacy Celularity and served as Vice Chairman of its board of directors from 2016. Dr. Diamandis is also the Founder and Executive Chairman of the XPRIZE Foundation, a non profit foundation that has designed and operated large scale incentive competitions and the Executive Founder of Singularity University, a graduate level Silicon Valley institution founded in 2008 that counsels the world's leaders on exponentially growing technologies. Dr. Diamandis is the Vice Chairman and co Founder of Human Longevity, Inc., a company focused on extending the human lifespan. Dr. Diamandis currently serves on the boards of Vaxxinity and DPCM Capital, and SWAG III (Nasdaq: SWAG).
- Diane Parks
-
Diane Parks自2022年6月起担任Celularity Inc.董事会成员。从2016年2月到2018年7月，Parks女士担任高级副总裁兼美国商业主管的Kite Pharma, Inc.是一家上市生物制药公司，该公司被Gilead收购，在那里她开发并执行了Yescarta商业发布的战略计划，Yescarta是首个获批用于大B细胞淋巴瘤的CAR T疗法。从2014年10月到2015年10月，Parks女士在被艾伯维公司收购的上市生物制药公司Pharmacyclics, Inc.担任副总裁兼全球营销主管，负责Imbruvica的营销战略和发布。2007年至2014年，她担任副总裁，负责上市生物技术公司安进的销售，在那里她成功地领导了医院和肾病学销售团队。1999年至2002年，她曾担任公众持股的生物技术公司基因泰克的专业生物治疗和管理式护理高级副总裁，该公司被F. Hoffmann La Roche AG收购。她目前在公有生物制药公司Calliditas Therapeutics AB、公有生物制药公司CTI BioPharma Corp.、公有生物制药公司Kura Oncology, Inc.、公有生物制药公司Soligenix, Inc.、公有生物制药公司TERM3、民营医疗器械公司TriSalus Life Sciences（前身为Surefire Medical，Inc.）和淋巴瘤研究基金会的董事会任职。帕克斯女士获得了乔治亚州立大学的工商管理硕士学位和堪萨斯州立大学的学士学位。
Diane Parks has served as a member of Celularity Inc.'s board of directors since June 2022. From February 2016 to July 2018, Ms. Parks served as Senior Vice President, Head of U.S. Commercial for Kite Pharma, Inc., a publicly held biopharmaceutical company, which was acquired by Gilead, where she developed and executed the strategic plan for the commercial launch of Yescarta, the first CAR T therapy approved for large B cell lymphoma. From October 2014 to October 2015, Ms. Parks served as Vice President, Head of Global Marketing for Pharmacyclics, Inc., a publicly held biopharmaceutical company, which was acquired by AbbVie, Inc., where she was responsible for the marketing strategy and launch of Imbruvica. From 2007 to 2014, she served as Vice President, Sales for Amgen, a publicly held biotechnology company, where she successfully led the hospital and nephrology sales teams. From 1999 to 2002, she served as Senior Vice President, Specialty Biotherapeutics and Managed Care for Genentech, Inc., a publicly held biotechnology company, which was acquired by F. Hoffmann La Roche AG. She currently serves on the boards of Calliditas Therapeutics AB, a publicly held biopharmaceutical company, CTI BioPharma Corp., a publicly held biopharmaceutical company, Kura Oncology, Inc., a publicly held biopharmaceutical company, Soligenix, Inc., a publicly held biopharmaceutical company, TriSalus Life Sciences (formerly Surefire Medical, Inc.), a privately held medical device company and the Lymphoma Research Foundation. Ms. Parks earned an M.B.A. from Georgia State University and a B.S. from Kansas State University. - Diane Parks自2022年6月起担任Celularity Inc.董事会成员。从2016年2月到2018年7月，Parks女士担任高级副总裁兼美国商业主管的Kite Pharma, Inc.是一家上市生物制药公司，该公司被Gilead收购，在那里她开发并执行了Yescarta商业发布的战略计划，Yescarta是首个获批用于大B细胞淋巴瘤的CAR T疗法。从2014年10月到2015年10月，Parks女士在被艾伯维公司收购的上市生物制药公司Pharmacyclics, Inc.担任副总裁兼全球营销主管，负责Imbruvica的营销战略和发布。2007年至2014年，她担任副总裁，负责上市生物技术公司安进的销售，在那里她成功地领导了医院和肾病学销售团队。1999年至2002年，她曾担任公众持股的生物技术公司基因泰克的专业生物治疗和管理式护理高级副总裁，该公司被F. Hoffmann La Roche AG收购。她目前在公有生物制药公司Calliditas Therapeutics AB、公有生物制药公司CTI BioPharma Corp.、公有生物制药公司Kura Oncology, Inc.、公有生物制药公司Soligenix, Inc.、公有生物制药公司TERM3、民营医疗器械公司TriSalus Life Sciences（前身为Surefire Medical，Inc.）和淋巴瘤研究基金会的董事会任职。帕克斯女士获得了乔治亚州立大学的工商管理硕士学位和堪萨斯州立大学的学士学位。
- Diane Parks has served as a member of Celularity Inc.'s board of directors since June 2022. From February 2016 to July 2018, Ms. Parks served as Senior Vice President, Head of U.S. Commercial for Kite Pharma, Inc., a publicly held biopharmaceutical company, which was acquired by Gilead, where she developed and executed the strategic plan for the commercial launch of Yescarta, the first CAR T therapy approved for large B cell lymphoma. From October 2014 to October 2015, Ms. Parks served as Vice President, Head of Global Marketing for Pharmacyclics, Inc., a publicly held biopharmaceutical company, which was acquired by AbbVie, Inc., where she was responsible for the marketing strategy and launch of Imbruvica. From 2007 to 2014, she served as Vice President, Sales for Amgen, a publicly held biotechnology company, where she successfully led the hospital and nephrology sales teams. From 1999 to 2002, she served as Senior Vice President, Specialty Biotherapeutics and Managed Care for Genentech, Inc., a publicly held biotechnology company, which was acquired by F. Hoffmann La Roche AG. She currently serves on the boards of Calliditas Therapeutics AB, a publicly held biopharmaceutical company, CTI BioPharma Corp., a publicly held biopharmaceutical company, Kura Oncology, Inc., a publicly held biopharmaceutical company, Soligenix, Inc., a publicly held biopharmaceutical company, TriSalus Life Sciences (formerly Surefire Medical, Inc.), a privately held medical device company and the Lymphoma Research Foundation. Ms. Parks earned an M.B.A. from Georgia State University and a B.S. from Kansas State University.
- Steven N. Gordon
-
Steven N. Gordon自2026年6月19日起担任Celularity Inc.的首席运营和行政官以及董事。他此前于2026年1月开始担任Celularity Inc.执行副总裁，商务事务。Gordon co先生创立了一家公开上市的生物制药公司，该公司于2021年以约19亿美元的价格被收购。他是Gordon Law的创始人和负责人，自1999年以来，他一直担任该公司的管理律师，在州和联邦法院代表私营和上市公司和个人处理复杂的民事和刑事事务。自1999年以来，他还担任Nevets，LLC的负责人，通过该公司，他参与了生物技术和医疗保健企业，包括生物技术初创公司和涉及临床阶段药物开发的项目。他目前担任勇士盾牌行动和南方大学的董事会成员。在职业生涯的早期，戈登曾在布朗克斯县地方检察官办公室担任助理地方检察官。他在Bar Ilan大学获得经济学和工商管理学士学位，在Touro College Jacob D. Fuchsberg法律中心获得法学博士学位。自1993年以来，他一直被允许从事法律工作，并在多个州和联邦法院被录取。
Steven N. Gordon has served as Celularity Inc.'s Chief Operating and Administrative Officer and a director since June 19, 2026. He previously served as Celularity Inc.'s Executive Vice President, Business Affairs beginning in January 2026. Mr. Gordon co founded a publicly traded biopharmaceutical company that was acquired in 2021 for approximately $1.9 billion. He is the founder and principal of Gordon Law, where he has served as managing attorney since 1999, representing private and public companies and individuals in complex civil and criminal matters in state and federal courts. He has also served as a principal of Nevets, LLC since 1999, through which he has been involved in biotechnology and healthcare ventures, including biotechnology startup companies and programs involving clinical stage drug development. He currently serves on the boards of Operation Warrior Shield and South University. Earlier in his career, Mr. Gordon served as an Assistant District Attorney in the Bronx County District Attorney's Office. He received a B.A. in Economics and Business Administration from Bar Ilan University and a J.D. from Touro College Jacob D. Fuchsberg Law Center. He has been admitted to practice law since 1993 and is admitted before various state and federal courts. - Steven N. Gordon自2026年6月19日起担任Celularity Inc.的首席运营和行政官以及董事。他此前于2026年1月开始担任Celularity Inc.执行副总裁，商务事务。Gordon co先生创立了一家公开上市的生物制药公司，该公司于2021年以约19亿美元的价格被收购。他是Gordon Law的创始人和负责人，自1999年以来，他一直担任该公司的管理律师，在州和联邦法院代表私营和上市公司和个人处理复杂的民事和刑事事务。自1999年以来，他还担任Nevets，LLC的负责人，通过该公司，他参与了生物技术和医疗保健企业，包括生物技术初创公司和涉及临床阶段药物开发的项目。他目前担任勇士盾牌行动和南方大学的董事会成员。在职业生涯的早期，戈登曾在布朗克斯县地方检察官办公室担任助理地方检察官。他在Bar Ilan大学获得经济学和工商管理学士学位，在Touro College Jacob D. Fuchsberg法律中心获得法学博士学位。自1993年以来，他一直被允许从事法律工作，并在多个州和联邦法院被录取。
- Steven N. Gordon has served as Celularity Inc.'s Chief Operating and Administrative Officer and a director since June 19, 2026. He previously served as Celularity Inc.'s Executive Vice President, Business Affairs beginning in January 2026. Mr. Gordon co founded a publicly traded biopharmaceutical company that was acquired in 2021 for approximately $1.9 billion. He is the founder and principal of Gordon Law, where he has served as managing attorney since 1999, representing private and public companies and individuals in complex civil and criminal matters in state and federal courts. He has also served as a principal of Nevets, LLC since 1999, through which he has been involved in biotechnology and healthcare ventures, including biotechnology startup companies and programs involving clinical stage drug development. He currently serves on the boards of Operation Warrior Shield and South University. Earlier in his career, Mr. Gordon served as an Assistant District Attorney in the Bronx County District Attorney's Office. He received a B.A. in Economics and Business Administration from Bar Ilan University and a J.D. from Touro College Jacob D. Fuchsberg Law Center. He has been admitted to practice law since 1993 and is admitted before various state and federal courts.
- Philip A. Barach
-
Philip A. Barach自2026年9月24日起担任Celularity Inc.董事会成员。巴拉赫先生是Vista Investment Group的首席执行官和管理成员，Vista Investment Group是一家私人持有的商业房地产投资公司，他于2008年共同创立。他共同创立了一家投资管理公司DoubleLine Capital LP，并在2020年4月退休前担任该公司总裁。在加入DoubleLine之前，Barach先生是TCW Group的集团董事总经理，此前曾担任CalPERS的首席固定收益官。
Philip A. Barach has served as a member of Celularity Inc.'s board of directors since September 24, 2026. Mr. Barach is Chief Executive Officer and Managing Member of Vista Investment Group, a privately held commercial real estate investment firm that he co founded in 2008. He co founded DoubleLine Capital LP, an investment management firm, and served as its President before retiring in April 2020. Before DoubleLine, Mr. Barach was a Group Managing Director at TCW Group and previously served as Principal Fixed Income Officer at CalPERS. - Philip A. Barach自2026年9月24日起担任Celularity Inc.董事会成员。巴拉赫先生是Vista Investment Group的首席执行官和管理成员，Vista Investment Group是一家私人持有的商业房地产投资公司，他于2008年共同创立。他共同创立了一家投资管理公司DoubleLine Capital LP，并在2020年4月退休前担任该公司总裁。在加入DoubleLine之前，Barach先生是TCW Group的集团董事总经理，此前曾担任CalPERS的首席固定收益官。
- Philip A. Barach has served as a member of Celularity Inc.'s board of directors since September 24, 2026. Mr. Barach is Chief Executive Officer and Managing Member of Vista Investment Group, a privately held commercial real estate investment firm that he co founded in 2008. He co founded DoubleLine Capital LP, an investment management firm, and served as its President before retiring in April 2020. Before DoubleLine, Mr. Barach was a Group Managing Director at TCW Group and previously served as Principal Fixed Income Officer at CalPERS.
高管简历
中英对照 | 中文 | 英文- Robert J. Hariri
Robert J. Hariri，是Legacy cellular的创始人，曾担任Celularity Inc.的董事。自2021年7月业务合并以来，他一直担任cellular Inc.的首席执行官兼董事长，自业务合并以来一直担任总裁，直到2021年9月，在业务合并之前，他是Legacy cellular的创始人，此前曾担任其总裁兼首席执行官，自2016年起担任董事会主席。Hariri博士从2015年9月起担任Cryoport的董事，从2020年6月起担任Biovie的董事。在加入Legacy Cellular之前，Hariri博士创立了Anthrogenesis Corporation并担任首席执行官，在该公司被Celgene收购后，Hariri博士从2005年到2013年担任Celgene Cellular Therapeutics的首席执行官。Hariri博士还共同创立了基于基因组的健康智能公司Human Longevity， Inc.和专注于长寿的Fountainlife。Hariri博士也是威尔-康奈尔大学医学院的神经外科兼职教授和研究员委员会成员。他是基因组学执政官X奖的X奖基金会科学顾问委员会成员。哈里里博士曾担任自由科学中心的受托人兼副主席。Hariri博士曾担任多家公司的董事会成员，包括Myos Corporation（2011年7月至2020年11月），2012年4月至2020年11月担任董事会主席，Bionik Laboratories Corp.（2015年3月至2017年10月）。Hariri博士获得哥伦比亚大学工程与应用科学学院和哥伦比亚学院生物人类学学士学位，以及Cornell大学医学博士和博士学位。
Robert J. Hariri is the founder of Celularity and has served as Celularity Inc.'s Chief Executive Officer and Chairman of the board of directors since the July 2021 business combination, after serving in those roles at Legacy Celularity from 2016. Dr. Hariri has also served as a director at BioVie since June 2020. Prior to joining Celularity, Dr. Hariri founded and served as Chief Executive Officer of Anthrogenesis Corporation, and after its acquisition by Celgene, Dr. Hariri served as Chief Executive Officer of Celgene Cellular Therapeutics from 2005 to 2013. Dr. Hariri also co founded the genomic based health intelligence company, Human Longevity, Inc. Dr. Hariri is also an Adjunct Professor of Neurosurgery and a member of the Board of Overseers at the Weill Cornell University Medical College. He is a member of the XPRIZE Foundation scientific advisory board for the Archon XPRIZE for Genomics. Dr. Hariri is a trustee and vice chair of the Liberty Science Center. Dr. Hariri has served as a member of the board of directors of various companies, including Myos Corporation from July 2011 to November 2020, where he served as Chairman of the board from April 2012 to November 2020, Bionik Laboratories Corp. from March 2015 to October 2017, Cryoport since September 2015. Dr. Hariri obtained an A.B. in Biological Anthropology from Columbia University School of Engineering and Applied Sciences and Columbia College and an M.D. and Ph.D. from Cornell University.- Robert J. Hariri，是Legacy cellular的创始人，曾担任Celularity Inc.的董事。自2021年7月业务合并以来，他一直担任cellular Inc.的首席执行官兼董事长，自业务合并以来一直担任总裁，直到2021年9月，在业务合并之前，他是Legacy cellular的创始人，此前曾担任其总裁兼首席执行官，自2016年起担任董事会主席。Hariri博士从2015年9月起担任Cryoport的董事，从2020年6月起担任Biovie的董事。在加入Legacy Cellular之前，Hariri博士创立了Anthrogenesis Corporation并担任首席执行官，在该公司被Celgene收购后，Hariri博士从2005年到2013年担任Celgene Cellular Therapeutics的首席执行官。Hariri博士还共同创立了基于基因组的健康智能公司Human Longevity， Inc.和专注于长寿的Fountainlife。Hariri博士也是威尔-康奈尔大学医学院的神经外科兼职教授和研究员委员会成员。他是基因组学执政官X奖的X奖基金会科学顾问委员会成员。哈里里博士曾担任自由科学中心的受托人兼副主席。Hariri博士曾担任多家公司的董事会成员，包括Myos Corporation（2011年7月至2020年11月），2012年4月至2020年11月担任董事会主席，Bionik Laboratories Corp.（2015年3月至2017年10月）。Hariri博士获得哥伦比亚大学工程与应用科学学院和哥伦比亚学院生物人类学学士学位，以及Cornell大学医学博士和博士学位。
- Robert J. Hariri is the founder of Celularity and has served as Celularity Inc.'s Chief Executive Officer and Chairman of the board of directors since the July 2021 business combination, after serving in those roles at Legacy Celularity from 2016. Dr. Hariri has also served as a director at BioVie since June 2020. Prior to joining Celularity, Dr. Hariri founded and served as Chief Executive Officer of Anthrogenesis Corporation, and after its acquisition by Celgene, Dr. Hariri served as Chief Executive Officer of Celgene Cellular Therapeutics from 2005 to 2013. Dr. Hariri also co founded the genomic based health intelligence company, Human Longevity, Inc. Dr. Hariri is also an Adjunct Professor of Neurosurgery and a member of the Board of Overseers at the Weill Cornell University Medical College. He is a member of the XPRIZE Foundation scientific advisory board for the Archon XPRIZE for Genomics. Dr. Hariri is a trustee and vice chair of the Liberty Science Center. Dr. Hariri has served as a member of the board of directors of various companies, including Myos Corporation from July 2011 to November 2020, where he served as Chairman of the board from April 2012 to November 2020, Bionik Laboratories Corp. from March 2015 to October 2017, Cryoport since September 2015. Dr. Hariri obtained an A.B. in Biological Anthropology from Columbia University School of Engineering and Applied Sciences and Columbia College and an M.D. and Ph.D. from Cornell University.
- K. Harold Fletcher
K. Harold Fletcher自2026年6月19日起担任Celularity Inc.的首席法律和战略官兼公司秘书，负责监督法律、公司治理、合规和战略举措，包括复杂的交易、融资、业务发展和关键的商业合作伙伴关系。他于2026年1月开始担任Celularity Inc.的法律和战略执行副总裁。此前，他曾于2022年10月至2025年12月期间担任Celularity Inc.执行副总裁兼总法律顾问，在此之前，担任Celularity Inc.高级副总裁、副总法律顾问兼首席合规官。自2018年1月加入Celularity担任高级公司法律顾问以来，Fletcher先生在公司的发展中发挥了不可或缺的作用，包括向上市公司的过渡、融资活动、战略交易以及法律和合规基础设施的发展。在加入Celularity之前，Fletcher先生于2015年至2018年在丨赛诺菲旗下公司Kadmon Corporation担任高级企业法律顾问，并于2012年至2015年在Sedgwick LLP担任生命科学和诉讼实践组的助理。Fletcher先生拥有Seton Hall大学的法学博士学位和罗格斯大学的政治学和历史学文学学士学位。
K. Harold Fletcher has served as Celularity Inc.'s Chief Legal and Strategy Officer and Corporate Secretary since June 19, 2026, overseeing legal, corporate governance, compliance and strategic initiatives, including complex transactions, financings, business development and key commercial partnerships. He served as Celularity Inc.'s Executive Vice President, Legal and Strategy beginning in January 2026. Previously, he served as Celularity Inc.'s Executive Vice President and General Counsel from October 2022 to December 2025 and, prior to that, as Celularity Inc.'s Senior Vice President, Deputy General Counsel and Chief Compliance Officer. Since joining Celularity in January 2018 as Senior Corporate Counsel, Mr. Fletcher has played an integral role in the Company's evolution, including its transition to a publicly traded company, capital raising activities, strategic transactions and development of its legal and compliance infrastructure. Before joining Celularity, Mr. Fletcher served as Senior Corporate Counsel at Kadmon Corporation, a Sanofi company, from 2015 to 2018 and as an associate in the life sciences and litigation practice groups at Sedgwick LLP from 2012 to 2015. Mr. Fletcher holds a Juris Doctor degree from Seton Hall University and a Bachelor of Arts degree in political science and history from Rutgers University.- K. Harold Fletcher自2026年6月19日起担任Celularity Inc.的首席法律和战略官兼公司秘书，负责监督法律、公司治理、合规和战略举措，包括复杂的交易、融资、业务发展和关键的商业合作伙伴关系。他于2026年1月开始担任Celularity Inc.的法律和战略执行副总裁。此前，他曾于2022年10月至2025年12月期间担任Celularity Inc.执行副总裁兼总法律顾问，在此之前，担任Celularity Inc.高级副总裁、副总法律顾问兼首席合规官。自2018年1月加入Celularity担任高级公司法律顾问以来，Fletcher先生在公司的发展中发挥了不可或缺的作用，包括向上市公司的过渡、融资活动、战略交易以及法律和合规基础设施的发展。在加入Celularity之前，Fletcher先生于2015年至2018年在丨赛诺菲旗下公司Kadmon Corporation担任高级企业法律顾问，并于2012年至2015年在Sedgwick LLP担任生命科学和诉讼实践组的助理。Fletcher先生拥有Seton Hall大学的法学博士学位和罗格斯大学的政治学和历史学文学学士学位。
- K. Harold Fletcher has served as Celularity Inc.'s Chief Legal and Strategy Officer and Corporate Secretary since June 19, 2026, overseeing legal, corporate governance, compliance and strategic initiatives, including complex transactions, financings, business development and key commercial partnerships. He served as Celularity Inc.'s Executive Vice President, Legal and Strategy beginning in January 2026. Previously, he served as Celularity Inc.'s Executive Vice President and General Counsel from October 2022 to December 2025 and, prior to that, as Celularity Inc.'s Senior Vice President, Deputy General Counsel and Chief Compliance Officer. Since joining Celularity in January 2018 as Senior Corporate Counsel, Mr. Fletcher has played an integral role in the Company's evolution, including its transition to a publicly traded company, capital raising activities, strategic transactions and development of its legal and compliance infrastructure. Before joining Celularity, Mr. Fletcher served as Senior Corporate Counsel at Kadmon Corporation, a Sanofi company, from 2015 to 2018 and as an associate in the life sciences and litigation practice groups at Sedgwick LLP from 2012 to 2015. Mr. Fletcher holds a Juris Doctor degree from Seton Hall University and a Bachelor of Arts degree in political science and history from Rutgers University.
- John M. Sprague
- 暂无中文简介
John M. Sprague serves as Celularity Inc.'s Chief Financial Officer and joined Celularity Inc. as Acting Chief Financial Officer on February 27, 2026. Before joining Celularity Inc., he served as Chief Financial Officer of Thread Research, a clinical trial software company. He previously served as Chief Financial Officer of T2 Biosystems, Inc. from January 2018 to April 2025 and of Caliber Imaging & Diagnostics, Inc. from February 2017 to January 2018. His earlier experience includes chief financial officer roles at GE Healthcare's North American Core Imaging pharmaceutical business and Xcellerex, Inc., which was acquired by GE Healthcare, and service as Vice President of Finance at RSA Security. He spent 12 years in Deloitte's technology audit practice, where he became a Senior Manager. Mr. Sprague is a Certified Public Accountant and holds a B.S. from Boston College's Carroll School of Management. - 暂无中文简介
- John M. Sprague serves as Celularity Inc.'s Chief Financial Officer and joined Celularity Inc. as Acting Chief Financial Officer on February 27, 2026. Before joining Celularity Inc., he served as Chief Financial Officer of Thread Research, a clinical trial software company. He previously served as Chief Financial Officer of T2 Biosystems, Inc. from January 2018 to April 2025 and of Caliber Imaging & Diagnostics, Inc. from February 2017 to January 2018. His earlier experience includes chief financial officer roles at GE Healthcare's North American Core Imaging pharmaceutical business and Xcellerex, Inc., which was acquired by GE Healthcare, and service as Vice President of Finance at RSA Security. He spent 12 years in Deloitte's technology audit practice, where he became a Senior Manager. Mr. Sprague is a Certified Public Accountant and holds a B.S. from Boston College's Carroll School of Management.
- Steven N. Gordon
Steven N. Gordon自2026年6月19日起担任Celularity Inc.的首席运营和行政官以及董事。他此前于2026年1月开始担任Celularity Inc.执行副总裁，商务事务。Gordon co先生创立了一家公开上市的生物制药公司，该公司于2021年以约19亿美元的价格被收购。他是Gordon Law的创始人和负责人，自1999年以来，他一直担任该公司的管理律师，在州和联邦法院代表私营和上市公司和个人处理复杂的民事和刑事事务。自1999年以来，他还担任Nevets，LLC的负责人，通过该公司，他参与了生物技术和医疗保健企业，包括生物技术初创公司和涉及临床阶段药物开发的项目。他目前担任勇士盾牌行动和南方大学的董事会成员。在职业生涯的早期，戈登曾在布朗克斯县地方检察官办公室担任助理地方检察官。他在Bar Ilan大学获得经济学和工商管理学士学位，在Touro College Jacob D. Fuchsberg法律中心获得法学博士学位。自1993年以来，他一直被允许从事法律工作，并在多个州和联邦法院被录取。
Steven N. Gordon has served as Celularity Inc.'s Chief Operating and Administrative Officer and a director since June 19, 2026. He previously served as Celularity Inc.'s Executive Vice President, Business Affairs beginning in January 2026. Mr. Gordon co founded a publicly traded biopharmaceutical company that was acquired in 2021 for approximately $1.9 billion. He is the founder and principal of Gordon Law, where he has served as managing attorney since 1999, representing private and public companies and individuals in complex civil and criminal matters in state and federal courts. He has also served as a principal of Nevets, LLC since 1999, through which he has been involved in biotechnology and healthcare ventures, including biotechnology startup companies and programs involving clinical stage drug development. He currently serves on the boards of Operation Warrior Shield and South University. Earlier in his career, Mr. Gordon served as an Assistant District Attorney in the Bronx County District Attorney's Office. He received a B.A. in Economics and Business Administration from Bar Ilan University and a J.D. from Touro College Jacob D. Fuchsberg Law Center. He has been admitted to practice law since 1993 and is admitted before various state and federal courts.- Steven N. Gordon自2026年6月19日起担任Celularity Inc.的首席运营和行政官以及董事。他此前于2026年1月开始担任Celularity Inc.执行副总裁，商务事务。Gordon co先生创立了一家公开上市的生物制药公司，该公司于2021年以约19亿美元的价格被收购。他是Gordon Law的创始人和负责人，自1999年以来，他一直担任该公司的管理律师，在州和联邦法院代表私营和上市公司和个人处理复杂的民事和刑事事务。自1999年以来，他还担任Nevets，LLC的负责人，通过该公司，他参与了生物技术和医疗保健企业，包括生物技术初创公司和涉及临床阶段药物开发的项目。他目前担任勇士盾牌行动和南方大学的董事会成员。在职业生涯的早期，戈登曾在布朗克斯县地方检察官办公室担任助理地方检察官。他在Bar Ilan大学获得经济学和工商管理学士学位，在Touro College Jacob D. Fuchsberg法律中心获得法学博士学位。自1993年以来，他一直被允许从事法律工作，并在多个州和联邦法院被录取。
- Steven N. Gordon has served as Celularity Inc.'s Chief Operating and Administrative Officer and a director since June 19, 2026. He previously served as Celularity Inc.'s Executive Vice President, Business Affairs beginning in January 2026. Mr. Gordon co founded a publicly traded biopharmaceutical company that was acquired in 2021 for approximately $1.9 billion. He is the founder and principal of Gordon Law, where he has served as managing attorney since 1999, representing private and public companies and individuals in complex civil and criminal matters in state and federal courts. He has also served as a principal of Nevets, LLC since 1999, through which he has been involved in biotechnology and healthcare ventures, including biotechnology startup companies and programs involving clinical stage drug development. He currently serves on the boards of Operation Warrior Shield and South University. Earlier in his career, Mr. Gordon served as an Assistant District Attorney in the Bronx County District Attorney's Office. He received a B.A. in Economics and Business Administration from Bar Ilan University and a J.D. from Touro College Jacob D. Fuchsberg Law Center. He has been admitted to practice law since 1993 and is admitted before various state and federal courts.